Abstract 393: Clinical impact of pentraxin family expression on prognosis in pancreatic carcinoma.

Abstract

Abstract Background: Inflammatory mediators may play decisive roles at different stages of tumor development. PTX3, a mediator that is a member of the pentraxin family, may be a biomarker for the early prognostic stratification of advanced pancreatic carcinoma patients. Methods: Enzyme-linked immunosorbent assay and cellular migration assay were performed to determine PTX3 concentrations in pancreatic carcinoma cell lines (ASPC-1, BXPC-3, MIAPACA-2 and PANC-1) PTX3 levels and other inflammatory mediators (IL-1beta, IL-6, CCL2, CCL3, CCL4, CCL7, CXCL9, and MIF) were validated in a subgroup of pancreatic carcinoma patients. Univariate and multivariate Cox analysis were performed to investigate the extent of PTX3 production in the cell lines and the differences in outcomes between patients with high and low levels of inflammatory mediators, who had been divided into high and low groups based on mean values. Results: In two cell lines (MIAPACA-2 and PANC-1), elevated PTX3 production was observed. A direct relationship was identified between migration activity and PTX3 level. In pancreatic carcinoma patients, median PFS was 76 days (95% confidence interval [CI], 43-109) in the PTX3high group and 150 days (95% CI, 131-197; P = 0.002) in the PTX3low group. Median OS was 117 days (95% CI, 82-152) in the PTX3high group and 357 days (95% CI, 239-475) in the PTX3low group (P < 0.001). Univariate and multivariate Cox model analysis of the pancreatic carcinoma clinical specimens revealed a strong correlation between pentraxin family member expression and PFS as well as OS. Examination of the relationship between PTX3 expression and the expression of other pro-inflammatory mediators indicated that PTX3 level is positively correlated with level of CRP, IL-6, and MIF. Conclusion: Thus, pentraxin family member, especially PTX3, is a promising biomarker for the prognosis of pancreatic carcinoma, and its expression can promote pancreatic carcinoma progression. Citation Format: Shunsuke Kondo, Hideki Ueno, Chigusa Morizane, Hiroko Hosoi, Fumiaki Koizumi, Kenji Tamura, Takuji Okusaka. Clinical impact of pentraxin family expression on prognosis in pancreatic carcinoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 393. doi:10.1158/1538-7445.AM2013-393